Med Biogene (MBI) Stock Price, News & Analysis

Company Overview

Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in identifying patients for adjuvant chemotherapy. The company has a collaboration agreement with the University Health Network in Toronto. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.05 to C$0.05
• 50-Day Range: C$0.05 to C$0.05
• 52-Week Range: C$0.02 to C$0.08
• Volume: 2,000 shs
• Average Volume: 29,135 shs
• Market Capitalization: C$596.61 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: CVE:MBI
• CIK: N/A
• Web: www.medbiogene.com
• Phone: +1-604-7327332
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 3.46
• Book Value: C$0.00 per share
• Price / Book: -45.00

Miscellaneous

• Outstanding Shares: 13,258,000
• Free Float: N/A
• Market Cap: C$596.61 thousand
• Optionable: Not Optionable
• Beta: N/A